Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exerted by these drugs is not greater than the one achieved with other classical glucose-lowering medications such as sulphonylureas. For that reason, plausible renoprotective mechanisms independent from glycaemic control have been proposed such as blood pressure control, body weight loss, intraglomerular pressure reduction and a decrease in urinary proximal tubular injury biomarkers. Interestingly, the hypothesis that SGLT2 inhibitors have a direct renoprotective effect has been addressed in diabetic and non-diabetic models. In this editorial, we update the different postulated mechanisms involved in the cardiorenal protection afforded by SGLT2 inhibition in chronic kidney disease.
SGLT2; Chronic kidney disease; Diabetic nephropathy
Vergara A, Jacobs-Cachá C, Soler MJ. Sodium-glucose cotransporter inhibitors: beyond glycaemic control. Clin Kidney J. 2019;12(3):322–5.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/4233
The following license files are associated with this item: